Literature DB >> 30635223

Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies.

Ana F Oliota1, Suelem T Penteado1, Fernanda S Tonin2, Fernando Fernandez-Llimos3, Andreia C Sanches4.   

Abstract

Colistin and polymyxin B are increasingly reintroduced in clinical practice due to the absence of effective antibiotics for the treatment of emerging infections caused by gram-negative bacteria. The synthesis of current evidence on the characteristics of polymyxins, especially regarding nephrotoxicity, is necessary. This study aims to conduct a systematic review and meta-analysis of cohort-type observational studies in order to identify the prevalence of nephrotoxicity in patients treated with either colistin or polymyxin B. PubMed, Scopus, and DOAJ electronic databases were searched, and manual searches were done. Cohort studies evaluating renal damage (nephrotoxicity) in adult patients caused by colistin or polymyxin B were included. Meta-analyses of the prevalence of nephrotoxicity as well as cumulative meta-analysis and meta-regression were conducted. After the systematic searches, 95 cohorts (n = 7911 patients) were included for analysis. The nephrotoxicity prevalence was 26.7% [confidence interval (CI) 95%: 22.8-30.9%] for colistin and 29.8% (CI 23.8-36.7%) for polymyxin B (P = 0.720). The publication year of the studies, the criteria used to classify renal damage, and the nephrotoxicity as primary or secondary outcome showed a significant influence on the adverse event rates.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Nephrotoxicity; Polymyxins; Prevalence; Renal failure; Systematic review; Toxicity

Mesh:

Substances:

Year:  2018        PMID: 30635223     DOI: 10.1016/j.diagmicrobio.2018.11.008

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  15 in total

1.  Cost-Effectiveness Analysis of New Beta-Lactam Beta-Lactamase Inhibitor Antibiotics Versus Colistin for the Treatment of Carbapenem-Resistant Infections.

Authors:  Monica L Bianchini; Meghan N Jeffres; Jonathan D Campbell
Journal:  Hosp Pharm       Date:  2020-12-29

2.  Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity.

Authors:  Kevin J Downes; Jennifer L Goldman
Journal:  Clin Pharmacol Ther       Date:  2021-02-27       Impact factor: 6.875

Review 3.  Polymyxin Delivery Systems: Recent Advances and Challenges.

Authors:  Natallia V Dubashynskaya; Yury A Skorik
Journal:  Pharmaceuticals (Basel)       Date:  2020-04-29

4.  Renal glycosuria as a novel early sign of colistin-induced kidney damage in mice.

Authors:  Sophia L Samodelov; Michele Visentin; Zhibo Gai; Stephanie Häusler; Gerd A Kullak-Ublick
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

Review 5.  Molecular Engineering of Polymyxin B for Imaging and Treatment of Bacterial Infections.

Authors:  Minghao Wu; Shipeng He; Hua Tang; Honggang Hu; Yejiao Shi
Journal:  Front Chem       Date:  2022-01-07       Impact factor: 5.221

6.  Ceftazidime-Avibactam versus Colistin for the Treatment of Infections Due to Carbapenem-Resistant Enterobacterales: A Multicenter Cohort Study.

Authors:  Thamer A Almangour; Leen Ghonem; Ahmad Aljabri; Alya Alruwaili; Mohammed Al Musawa; Nader Damfu; Mesfer S Almalki; Majda Alattas; Hossam Abed; Doaa Naeem; Nawaf Almalki; Abdullah A Alhifany
Journal:  Infect Drug Resist       Date:  2022-01-23       Impact factor: 4.003

7.  In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe.

Authors:  Christopher Longshaw; Davide Manissero; Masakatsu Tsuji; Roger Echols; Yoshinori Yamano
Journal:  JAC Antimicrob Resist       Date:  2020-08-25

8.  Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance study.

Authors:  Milo Gatti; Emanuel Raschi; Fabrizio De Ponti
Journal:  BMC Pharmacol Toxicol       Date:  2019-11-12       Impact factor: 2.483

9.  Colistin Nephrotoxicity: Meta-Analysis of Randomized Controlled Trials.

Authors:  Khalid Eljaaly; Monique R Bidell; Ronak G Gandhi; Samah Alshehri; Mushira A Enani; Ahmed Al-Jedai; Todd C Lee
Journal:  Open Forum Infect Dis       Date:  2021-01-21       Impact factor: 3.835

10.  Comparison of colistin-induced nephrotoxicity between two different formulations of colistin in critically ill patients: a retrospective cohort study.

Authors:  Jia-Yih Feng; Yi-Tzu Lee; Sheng-Wei Pan; Kuang-Yao Yang; Yuh-Min Chen; David Hung-Tsang Yen; Szu-Yuan Li; Fu-Der Wang
Journal:  Antimicrob Resist Infect Control       Date:  2021-07-30       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.